299 related articles for article (PubMed ID: 33973053)
21. Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.
Fujimoto A; Hiramoto N; Yamasaki S; Inamoto Y; Ogata M; Sugio Y; Fukuda T; Uchida N; Ikegame K; Matsuoka KI; Shiratori S; Kondo T; Miyamoto T; Eto T; Ichinohe T; Kanda Y; Atsuta Y; Suzuki R;
Hematol Oncol; 2020 Apr; 38(2):146-152. PubMed ID: 31953867
[TBL] [Abstract][Full Text] [Related]
22. Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients.
Traum AZ; Rodig NM; Pilichowska ME; Somers MJ
Pediatr Transplant; 2006 Jun; 10(4):505-12. PubMed ID: 16712612
[TBL] [Abstract][Full Text] [Related]
23. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
[TBL] [Abstract][Full Text] [Related]
24. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
25. Posttransplant lymphoproliferative disorders of the central nervous system after kidney transplantation: single center experience over 40 years. Two case reports.
Arita H; Izumoto S; Kinoshita M; Okita Y; Hashimoto N; Fujita T; Ichimaru N; Takahara S; Yoshimine T
Neurol Med Chir (Tokyo); 2010; 50(12):1079-83. PubMed ID: 21206182
[TBL] [Abstract][Full Text] [Related]
26. Presentation and outcomes of post-transplant lymphoproliferative disorder at a single institution pediatric transplant center.
Ramos-Gonzalez G; Crum R; Allain A; Agur T; O'Melia L; Staffa S; Burchett SK; Siegele B; Weinberg O; Rodig NM; Fawaz R; Singh TP; Freiberger DA; Bae Kim H
Pediatr Transplant; 2022 Aug; 26(5):e14268. PubMed ID: 35304794
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
Van Besien K; Bachier-Rodriguez L; Satlin M; Brown MA; Gergis U; Guarneri D; Hsu J; Phillips AA; Mayer SA; Singh AD; Soave R; Rossi A; Small CB; Walsh TJ; Rennert H; Shore TB
Leuk Lymphoma; 2019 Jul; 60(7):1693-1696. PubMed ID: 30741059
[TBL] [Abstract][Full Text] [Related]
28. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
González-Barca E; Capote FJ; Gómez-Codina J; Panizo C; Salar A; Sancho JM; López A; Briones J; Muñoz A; Encuentra M; Mercadal S; Domingo-Domenech E; de Sevilla AF;
Ann Hematol; 2021 Apr; 100(4):1023-1029. PubMed ID: 32367180
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
31. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.
Jagadeesh D; Woda BA; Draper J; Evens AM
Curr Treat Options Oncol; 2012 Mar; 13(1):122-36. PubMed ID: 22241590
[TBL] [Abstract][Full Text] [Related]
32. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
33. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
[TBL] [Abstract][Full Text] [Related]
34. Hypogammaglobulinemia and bacterial infections following pediatric post-transplant lymphoproliferative disorder in the rituximab era.
Chiou FK; Beath SV; Patel M; Gupte GL
Pediatr Transplant; 2019 Sep; 23(6):e13519. PubMed ID: 31209964
[TBL] [Abstract][Full Text] [Related]
35. Primary Central Nervous System Post-transplant Lymphoproliferative Disorder Misdiagnosed as Glioblastoma: A Case Report.
Tanaka H; Matsuda R; Nakamura M; Nakagawa I; Nakase H
Anticancer Res; 2022 Aug; 42(8):3975-3979. PubMed ID: 35896237
[TBL] [Abstract][Full Text] [Related]
36. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland.
Steiner R; Kridel R; Giostra E; McKee T; Achermann R; Mueller N; Manuel O; Dickenmann M; Schuurmans MM; de Leval L; Fehr T; Tinguely M; Binet I; Cogliatti S; Haralamvieva E; Koller M; The Swiss Transplant Cohort Study Stcs ; Dietrich PY
Swiss Med Wkly; 2018; 148():w14596. PubMed ID: 29518251
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy.
Said-Conti V; Amrolia PJ; Gaze MN; Stoneham S; Sebire N; Shroff R; Marks SD
Pediatr Nephrol; 2013 Oct; 28(10):2053-6. PubMed ID: 23743853
[TBL] [Abstract][Full Text] [Related]
38. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
[TBL] [Abstract][Full Text] [Related]
39. EBV-positive post-transplant lymphoproliferative disorder presenting as primary diffuse large B-cell lymphoma of the central nervous system.
Xu H; Rewerska J; Aardsma N; Slavin K; Valyi-Nagy T; Ni H
Folia Neuropathol; 2017; 55(3):221-226. PubMed ID: 28984115
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders.
Choi JH; Park BB; Suh C; Won JH; Lee WS; Shin HJ
J Korean Med Sci; 2010 Apr; 25(4):523-6. PubMed ID: 20357991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
